Chang Albert J, Dehdashti Farrokh, Bradley Jeffrey D
Department of Radiation Oncology, Mallinckrodt Institute of Radiology, St Louis, Missouri.
Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, St Louis, Missouri; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.
Pract Radiat Oncol. 2011 Oct-Dec;1(4):282-8. doi: 10.1016/j.prro.2011.01.001. Epub 2011 May 6.
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. 2-deoxy-2-((18)F)fluoro-D-glucose (FDG) positron emission tomography (PET) fused with computed tomography (CT) has become the standard of care in the initial staging of patients with non-small cell lung cancer and has been increasingly utilized for radiation treatment planning as disease extent and tumor volumes are better defined than CT alone. The biologic information from FDG-PET may be used for predicting outcome, assessing treatment response, and surveillance imaging. Addition of respiratory gating to PET reduces motion artifacts to improve tumor delineation. Novel radiotracers are being investigated to provide further biological information such as tumor hypoxia and cell proliferation.
肺癌是第二大常见癌症，也是癌症相关死亡的主要原因。2-脱氧-2-（[18F]）氟-D-葡萄糖（FDG）正电子发射断层扫描（PET）与计算机断层扫描（CT）融合，已成为非小细胞肺癌患者初始分期的标准治疗方法，并且由于与单独的CT相比，能够更好地确定疾病范围和肿瘤体积，因此越来越多地用于放射治疗计划。来自FDG-PET的生物学信息可用于预测预后、评估治疗反应和监测成像。在PET中添加呼吸门控可减少运动伪影，以改善肿瘤轮廓的描绘。正在研究新型放射性示踪剂，以提供更多的生物学信息，如肿瘤缺氧和细胞增殖情况。
